Lixte Biotechnology Holdings, Inc (LIXTW)

Etorro trading 970x250
Lixte Biotechnology Holdings, Inc (LIXTW) Logo

About Lixte Biotechnology Holdings, Inc

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher’s disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and study with the National Cancer Institute. The company was founded in 2005 and is based in East Setauket, New York. Address: 248 Route 25A, No. 2, East Setauket, NY, United States, 11733

Lixte Biotechnology Holdings, Inc News and around…

Latest news about Lixte Biotechnology Holdings, Inc (LIXTW) common stock and company :

Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
20 Oct, 2021 Yahoo! Finance

Studies to use genome wide functional genetic techniques to identify effective drug combinations and new drug targets for its lead clinical compound, LB-100 PASADENA, CA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the Benzinga Global Small Cap Conference being held virtually October 27-28, 2021. Event and Registration: Benzinga G

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment
13 Oct, 2021 Yahoo! Finance

PASADENA, CA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam (NKI) , one of the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific m

We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth
24 Sep, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
17 Aug, 2021 Yahoo! Finance

A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte”), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, noted that in pre-clinical studies its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to re

LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY
03 Aug, 2021 Yahoo! Finance

A Pre-Clinical Study Reports that LB-100 Potentiates Standard Therapy for Small Cell Lung Cancer Providing a Strong Rationale for a Clinical Trial of LB-100 in Small Cell Lung Cancer Recently Initiated at City of Hope. Pasadena, CA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT) announced that its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard therapy in models of sma

LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
22 Jul, 2021 Yahoo! Finance

Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer treatments, commented on pre-clinical research demonstrating that inhibition of protein phosphatase 2A (PP2A) with LB-100 combined with the experimental drug, vosoritide (BioMarin), was even more effective than vosorotide alone in stimulating bone length and cartilage area in a mouse model of the m

Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer
13 Jul, 2021 Yahoo! Finance

Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine’s Cancer Biology program, was selected for the second time to receive the National Latino Leader Award and a scholarship to present virtually studies of LB-100 in triple negative breast cancer (TNBC) at the 2021 Society of Advancing Chicanos/Hispanics and Native Ameri

Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021
07 Jul, 2021 Yahoo! Finance

Presentation to highlight Company’s current clinical study of lead compound LB-100 for Small Cell Lung Cancer ALTADENA, CA, July 07, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“Lixte” or the “Company”), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the MoneyShow July Virtual Expo taking place July 13-15, 2021. Registration is free and open to the public. Event and Registration: Money

WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc.
01 Dec, 2020 Yahoo! Finance

WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of a joint underwritten public offering of 1,200,000 shares for Lixte Biotechnology Holdings, Inc. (NASDAQ: Common stock – LIXT; Warrants – LIXTW) at an offering price of $4.75 per unit for total gross proceeds of $5.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses and before any exercise of the underwriters' overallotment option. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $5.70 per share. In addition, Lixte has granted the underwriters a 45-day option to purchase up to 180,000 additional shares of the Company's common stock and/or up to 180,000 additional warrants to purchase shares of the Company's common stock, or any combination thereof, to cover overallotments, if any. The shares and warrants began trading on The NASDAQ Capital Market on Wednesday, November 25, 2020, under the symbols "LIXT" and "LIXTW", respectively.

Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq
01 Dec, 2020 FinancialContent
WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)
30 Nov, 2020 FinancialContent

WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the closing of the follow-on offering for its client Lixte Biotechnology Holdings, Inc. 1,200,000 units consisting of one share of common stock and one warrant were sold for a total of $5,700,000 in gross proceeds. Lixte Biotechnology Holdings, Inc. began trading on The Nasdaq Capital Market ("Nasdaq") on Wednesday, November 25, 2020 under the trading symbols "LIXT" and “LIXTW”.

Lixte Biotechnology Holdings, Inc (LIXTW) is a NASDAQ Common Stock listed in

970x250